

Available online at http://www.journalcra.com

INTERNATIONAL JOURNAL OF CURRENT RESEARCH

International Journal of Current Research Vol. 12, Issue, 08, pp. 13031-13033, August, 2020

DOI: https://doi.org/10.24941/ijcr.39485.08.2020

RESEARCH ARTICLE

AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1 WITH END STAGE RENAL DISEASE; RARE PRESENTATION WITH NOVEL ALLELIC VARIANT: A CASE REPORT

^{1,*}Abdullah Saad Alshahrany, ²Mohammed S. Alshahrani and ³Ahmed H. Al-Ghamdi

¹Pediatric and Diabetes Consultant, Department of Pediatric , Armed Forces Hospital Southern Region, Khamis Mushayt, Kingdom of Saudi Arabia

²Dermatology and Venereology Consultant, Department of Dermatology, Armed Forces Hospital Southern Region, Khamis Mushayt, Kingdom of Saudi Arabia

³Associate Professor, Department of Pediatric, Al Baha faculty of Medicine, Al Baha University Kingdom of Saudi Arabia

ARTICLE INFO	ABSTRACT
Article History: Received 10 th May, 2020 Received in revised form 21 st June, 2020 Accepted 20 th July, 2020 Published online 30 th August, 2020	Au toi mmune polyendocrinopathy syndrome type 1 is a rare disease caused by mutations in the autoi mmune regulator gene (AIRE) leading to immune injury of multiple organs (mainly endocrine). We describe a case with autoimmune polyendocrinopathy syndrome type 1 presented with features of chronic muco cutaneous candidiasis and hypoparathyroidism. End stage renal disease was found and the renal biopsy confirmed tubulo-interstitial nephritis which is very rarely encountered in these patients. Molecular genetic analysis of AIRE gene showed homozygous variant c.274C>T p.
Kev Words:	(Arg92 Trp) which is classified as pathogenic.

Autoimmune poly endocrinopathy

syndrome type 1, AIRE, tubulo-interstitial nephritis, hypoparathyroidism.

Copyright © **2020**, **Abdullah Saad Alshahrany et al.** This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Abdullah Saud Alshahrany, Mohammed S. Alshahrani and Ahmed H. Al-Ghamdi. 2020. "Autoimmure polyglandular syndrome type 1 with end stage renal disease; rare presentation with novel a lelic variant: a case report", International Journal of Current Research, 12, (08), 13031-13033.

INTRODUCTION

Autoimmune polyendocrine syndrome type 1 (APS-1), also polyendocrinopathy named autoimmune candidiasis ectodermal dystrophy (APECED) is a rare disease with autosomal recessive pattern of inheritance (Eystein, 2018). Mutations in the autoimmune regulator gene (AIRE) lead to this disease. AIRE clearly plays a crucial role in preventing organ-specific autoimmunity. It regulates the expression of ectopic proteins expressed by medullary thymic epithelial cells which contribute significantly to central tolerance; thus preventing autoimmunity and production of autoantibodies (Notarangelo, 2004; Peterson, 2004). Autoimmune polyendocrine syndrome type 1 is characterized by the development of at least two of three cardinal components during childhood; chronic mucocutaneous candidiasis, and primary adrenal insufficiency hypoparathyroidism, (Addison's disease) (Husebye, 2009).

*Corresponding author: Abdullah Saad Alshahrany,

Pediatric and Diabetes Consultant, Department of Pediatric, Armed Forces Hospital Southem Region, Khamis Mushayt, Kingdom of Saudi Arabia. Other classic components are less frequent but may include bilateral keratitis, offen accompanied by severe photophobia, and periodic fever with rash, as well as autoimmune-induction of hepatitis, pneumonitis, nephritis, exocrine pancreatitis, and functional asplenia (Ahonen, 1990; Bruserud, 2016). Some cases with APS1 develop tubulointerstitial nephritis (TIN) and progress to end-stage renal failure (ESRD) and may recur in the transplanted kidney (Ulinski, 2006; Gwertzman, 2006).

Case Description

A13 years old Saudi child presented to ER with sever carpopedal spasm, discoloration of lips and mucocutaneous candidiasis of oral cavity, fingers and toes. Serum calcium was found to be very low 0.8 mmol/L (2.2 to 2.7 mmol/L) and the patient was euglycemic. Serum parathormone was 0.12pmol/L (1.28 -7.35 pmol/L) and adreno-cortico-trophic hormone (ACTH) was 203.5 pg/ml (4.7-48.8 pg/ml). Serum creatinine was highly elevated at 596.9 umol/L (27-88 umol/L) and blood urea Nitrogen (BUN) 35.5 mmol/L (2.5-7.85 mmol/L). The patient was anemic (hemoglobin 8.7, MCV 96, leukocytic count 6.4 and platelets 367). Vitamin B12 was found to be low at 118 pg/ml (201-1046 pg/ml).

Revision of the recommended autoantibodies revealed parietal cells antibodies titer >1:10(positive), tissue transglutaminase antibodies IgA 307 U/ml (normal < 7), Islet cell antibodies 1:160 (highly positive+++/ normal < 10), Glutamic acid decarboxylase (GAD65) antibodies>2000IU/ml (normal < 10), 21-hydroxylase antibodies 12.9 (normal < 10.0), Thyroid peroxidase (TPO) antibodies 33.24 IU/ml (normal < 5.6). Serum TSH, T3, T4, liver functions testsand hemoglobin A1C were found to be normal. For complete assessment of the kidneys; a renal biopsy through a True-cut left kidney was taken and showed moderate interstitial fibrosis and tubular atrophy. There was tubulo-interstitial nephritis (TIN) of 130 glomeruli (Figure 1).



Figure 1. Moderate interstitial fibrosis, tubular atrophy and tubulo-interstitial nephritis (TIN).



Figure 2. Schematic Structure of the Autoimmune Regulator Gene with Indica tio ns of Major Mutations and Functional Domains (1). Founder mutations (red): R257X, Finland; Y85C, Persian Jews; R139X, Sardinia R203X, p.C332del13 Sicily, The 13 bp mutation, common (black). Dominant negative mutations (green): p.G 228 W, p.R247C, p.E298 K, p.V301 M, p.C302 Y, p.R303 W, p.G 305 S, p.C311Y, p.R316W, p.P326L, p.R328Q. Frequencies of mutations in the general population (gray) based on data from the Exome **Aggregation Consortium**

Molecular genetic analysis of AIRE gene (the coding exons of the AIRE gene were enriched using Roch/NimbleGen sequence capture technology and sequenced on an illumina system (next-generation sequencing, NGS)) which showed homozygous variant c.274C>T p.(Arg92Trp) in the AIRE. The variant has already been described in the literature in a family with APS 1. Allele frequency of this variant in general population has not been documented (gnomAD) and this is the first time we detect it in the database. Considering the available information, the variant is classified as pathogenic. Patient was treated with elemental calcium and al facalcidol. At

Patient was treated with elemental calcium and alfacalcidol. At the follow up; eucalcemia was achieved. Dermatology team was involved and the patient is under regular follow up for any complications that may develop any time. Patient was started on haemo-dialysis, and listed for renal transplant.

DISCUSSION

Autoimmune regulator gene (AIRE) mutations are cause of a rare autoimmune disease named autoimmune polyglandularsyndrome type 1. The patients usually present with classic diagnostic dyad/triad of mucocutaneous candidiasis, hypoparathyroidism, and adrenocortical failure (Eystein, 2018). Besides the classical triad, a dozen autoimmune endocrine and other components may be encountered. Other features may include keratoconjunctivitis, hepatitis, chronic diarrhea, periodic rash with fever. Prevalence of most components increases with age, hypothyroidism, diabetes mellitus and testicular failure frequency is higher toward middle age (Perheentupa, 2006). Our case is a Saudi child that presented with clinical features of hypoparathyroidism with hypocalcemia causing carpopedalspasm and mucocutaneous candidiasis. The triad was competed with the elevated serum ACTH level denoting presence of Addison's disease. Some other autoimmune features were discovered as pernicious anemia, thyroid autoantibodies and pancreatic autoantibodies.

Renal functions assessment of our patient revealed features of ESRD. Renal biopsy revealed interstitial fibrosis, tubular atrophy and tubulo-interstitial nephritis TIN. To the best of our knowledge, this is the first report of a Saudi Muslim APS-1 child with TIN leading to ESRD. In the Finnish series of patients, which is the largest internationally; TIN occurred in 8 patients (Perheentupa , 2006). Ulinski et al. (2006) were the first to report an APECED patient with chronic intestinal nephritis leading to ESRD. They found that clinical and biological improvement was observed under post-transplant immunosuppression drugs; tacrolimus and mycophenolate mofetil. Two patients with APS 1 and TIN were described by Gwertzman et al. (9).

TIN was clinically silent in both cases and the diagnosis was confirmed by renal biopsy. In one patient, renal function remained stable with immunosuppressive therapy. A second patient, despite treatment, progressed to ESRD and received a deceased donor allograft. Surprisingly; TIN recurred in the transplanted kidney but was reversed successfully with rituximab. Molecular genetic analysis of AIRE gene in our patient revealed homozygous variant c.274C>T p. (Arg92Trp). Many different mutations have been reported (Figure 2). The most common is the so-called Finnish major mutation, p.R257X located in the SAND-domain (named after a range of proteins in the protein family: Sp100, AIRE-1, NucP41/75, DEAF-1). The Finnish major mutation is especially prevalent in people in Finland, Russia, and Eastern Europe (Bruserud, 2016; Orlova , 2017).

Conclusion

In this patient with this new allele variant with TIN presentation is an important complication of APS 1 that may result in ESRD. It is recommended to keep in mind that TIN may recur in the transplanted kidney based on few past reports. The presentation of TIN may be unapparent clinically with normal urinalysis, so, it is advised to well investigate for its presence.

Statement of Ethics

There are no ethical conflicts to declare. There is no identifying patient in formation in the manuscript. An informed written consent was taken from the father of the patient. It has been approved by the local ethics committee.

Conflict of Interest Statement: The authors have nothing to disclose.

Funding Sources: The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in the manuscript.

REFERENCES

- Ahonen P, Myllamiemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829–36.
- Bruserud O, Offedal BE, Landegren N, et al. A longitudinal follow-up of Autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2016;101:2975–83.
- Bruserud O, Offedal BE, Wolff AB, Husebye ES. AIREmutations and autoimmune disease. *Curr Opin Immunol*. 2016;43:8–15.
- Eystein S. Husebye, Mark S. Anderson, Olle K\u00e4mpe. Autoimmune Polyendocrine Syndromes. N Engl J Med. 2018 Mar 22; 378(12): 1132–1141.
- Gwertzman R, Corey H, Roberti I. Autoimmune polyglandular syndrome type I can have signi ficant kidney disease in children including recurrence in renal allograft - a report of two cases. Clin Nephrol. 2016 Jun;85(6):358-62.

- Husebye ES, Perheentupa J, Rautemaa R, Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. 2009;265:514–29.
- Notarangelo LD, Mazza C, Forino C, Mazzolari E, Buzi F. AIRE and immunological tolerance: insights from the study of autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy. Current Opinion in Allergy and Clinical Immunology. 2004;4(6):491–496.
- Orlova EM, Sozaeva LS, Kareva MA, et al. 2017. Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab., 102:3546–56.
- Perheentupa J. 2006. Autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. Aug;91(8):2843-50.
- Peterson P, Pitkänen J, Sillanpää N, Krohn K. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clinical and Experimental Immunology. 2004;135(3):348–357.
- Pollak U, Bar-Sever Z, Hoffer V, Marcus N, ScheuemanO, Garty BZ. Asplenia and functional hyposplenism in autoimmune polyglandular syndrome type 1. Eur J Pediatr. 2009;168:233–5.
- Ulinski T, Perrin L, Morris M, Houang M, Cabrol S, Grapin C, Chabbert-Bu ffet N, Bensman A, Deschênes G, Giurgea I. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure: impact of posttransplant immunosuppression on disease activity. J Clin Endocrinol Metab. 2006 Jan;91(1):192-5.
